001     289032
005     20240425125345.0
024 7 _ |2 doi
|a 10.3389/fragi.2023.1258184
024 7 _ |2 pmid
|a pmid:38500495
024 7 _ |2 pmc
|a pmc:PMC10944877
024 7 _ |a altmetric:160324452
|2 altmetric
037 _ _ |a DKFZ-2024-00564
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Falckenhayn, Cassandra
|b 0
245 _ _ |a Identification of dihydromyricetin as a natural DNA methylation inhibitor with rejuvenating activity in human skin.
260 _ _ |a Lausanne
|b Frontiers Media S.A.
|c 2023
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1710856962_17309
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
500 _ _ |a DKFZ-ZMBH Alliance
520 _ _ |a Changes in DNA methylation patterning have been reported to be a key hallmark of aged human skin. The altered DNA methylation patterns are correlated with deregulated gene expression and impaired tissue functionality, leading to the well-known skin aging phenotype. Searching for small molecules, which correct the aged methylation pattern therefore represents a novel and attractive strategy for the identification of anti-aging compounds. DNMT1 maintains epigenetic information by copying methylation patterns from the parental (methylated) strand to the newly synthesized strand after DNA replication. We hypothesized that a modest inhibition of this process promotes the restoration of the ground-state epigenetic pattern, thereby inducing rejuvenating effects. In this study, we screened a library of 1800 natural substances and 640 FDA-approved drugs and identified the well-known antioxidant and anti-inflammatory molecule dihydromyricetin (DHM) as an inhibitor of the DNA methyltransferase DNMT1. DHM is the active ingredient of several plants with medicinal use and showed robust inhibition of DNMT1 in biochemical assays. We also analyzed the effect of DHM in cultivated keratinocytes by array-based methylation profiling and observed a moderate, but significant global hypomethylation effect upon treatment. To further characterize DHM-induced methylation changes, we used published DNA methylation clocks and newly established age predictors to demonstrate that the DHM-induced methylation change is associated with a reduction in the biological age of the cells. Further studies also revealed re-activation of age-dependently hypermethylated and silenced genes in vivo and a reduction in age-dependent epidermal thinning in a 3-dimensional skin model. Our findings thus establish DHM as an epigenetic inhibitor with rejuvenating effects for aged human skin.
536 _ _ |0 G:(DE-HGF)POF4-311
|a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |2 Other
|a DNA methylation
650 _ 7 |2 Other
|a DNAm age clock
650 _ 7 |2 Other
|a DNMT1 inhibition
650 _ 7 |2 Other
|a dihydromyricetin
650 _ 7 |2 Other
|a rejuvenation
650 _ 7 |2 Other
|a skin
700 1 _ |a Bienkowska, Agata
|b 1
700 1 _ |a Söhle, Jörn
|b 2
700 1 _ |a Wegner, Katrin
|b 3
700 1 _ |0 P:(DE-HGF)0
|a Raddatz, Guenter
|b 4
700 1 _ |a Kristof, Boris
|b 5
700 1 _ |a Kuck, Dirk
|b 6
700 1 _ |a Siegner, Ralf
|b 7
700 1 _ |a Kaufmann, Ronny
|b 8
700 1 _ |a Korn, Julia
|b 9
700 1 _ |a Baumann, Sascha
|b 10
700 1 _ |a Lange, Daniela
|b 11
700 1 _ |a Schepky, Andreas
|b 12
700 1 _ |a Völzke, Henry
|b 13
700 1 _ |a Kaderali, Lars
|b 14
700 1 _ |a Winnefeld, Marc
|b 15
700 1 _ |0 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
|a Lyko, Frank
|b 16
|u dkfz
700 1 _ |a Grönniger, Elke
|b 17
773 _ _ |0 PERI:(DE-600)3076785-4
|a 10.3389/fragi.2023.1258184
|g Vol. 4, p. 1258184
|p 1258184
|t Frontiers in aging
|v 4
|x 2673-6217
|y 2023
909 C O |o oai:inrepo02.dkfz.de:289032
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-HGF)0
|a Deutsches Krebsforschungszentrum
|b 4
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
|a Deutsches Krebsforschungszentrum
|b 16
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-311
|1 G:(DE-HGF)POF4-310
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2023
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2023-09-02
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2023-09-02
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2021-07-13T13:40:23Z
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2021-07-13T13:40:23Z
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Anonymous peer review
|d 2021-07-13T13:40:23Z
915 _ _ |0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|a Creative Commons Attribution CC BY (No Version)
|b DOAJ
|d 2021-07-13T13:40:23Z
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2023-09-02
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2023-09-02
920 1 _ |0 I:(DE-He78)A130-20160331
|k A130
|l A130 Epigenetik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A130-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21